Zacks.com on MSN17h
CHMP Endorses AstraZeneca's Tagrisso for Expanded Use in NSCLC
The CHMP's opinion is based on late-stage data, which show that treatment with AZN's Tagrisso extends progression-free ...
Zacks.com on MSN1d
CHMP Endorses J&J's Rybrevant-Lazcluze Combo for Use in NSCLC
Johnson & Johnson JNJ announced that the EMA’s Committee for Medicinal Products for Human Use (“CHMP”) recommended approving ...
Zacks.com on MSN1d
Merck Gets Positive CHMP Opinion for Keytruda in Mesothelioma
Committee for Medicinal Products for Human Use (CHMP) has rendered a positive opinion, recommending the approval of its ...
GlobalData on MSN2d
EMA’s CHMP to approve BMS’ Opdivo for colorectal cancer
The EMA's CHMP has recommended approval of a combination therapy of BMS's Opdivo and Yervoy for the treatment of colorectal ...
GlobalData on MSN22h
CHMP recommends AstraZeneca’s Tagrisso for EU approval for NSCLC
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended AstraZeneca's Tagrisso ...
Business Insider2d
CHMP Recommends Approval Of Lazcluze + Rybrevant In EU For EGFR-mutated Advanced NSCLC
(RTTNews) - Janssen-Cilag International NV, a Johnson & Johnson company (JNJ), Monday said that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended ...
GlobalData on MSN5d
EMA’s CHMP recommends Sanofi’s Sarclisa approval for multiple myeloma
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of ...
InflaRx receives positive CHMP opinion for GOHIBIC for SARS-CoV-2-induced ARDS
InflaRx (IFRX) announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive ...
FiercePharma4d
EU regulators endorse meds from BMS, J&J, Eisai and more—plus a clutch of biosims
Now, it's up to the European Commission to confirm those potential green lights in the coming weeks and months.
The Pharma Letter4d
EMA/CHMP November recommendations include Leqembi U-turn
The European Medicines Agency’s (EMA) human medicines committee (CHMP) made a number of recommendations at its November ...
PharmiWeb2d
Formycon receives positive CHMP opinion for FYB203…
Statement/Regulatory AdmissionFormycon receives positive CHMP opinion for FYB203 (aflibercept), a biosimilar candidate to Eylea® under the tradenames AHZANTIVE® and Baiama® 18.11.2024 / 06:30 ...
Medscape4d
Leqembi Okayed for Subset of Early Alzheimer’s Patients
The European Medicines Agency re-examined clinical data of a subset of patients with one or no copies of the APOE4 gene ...